What Ennovation Ventures does

Ennovation Ventures (恩然创投) is a privately-held venture capital firm founded in 2015 and headquartered in Shanghai with a registered entity in Nanjing (南京恩然瑞光投资管理中心（有限合伙）). The firm specializes in equity investments across the global biopharmaceutical and medical health industry chain, focusing on revolutionary new technologies and products in life sciences, healthcare, and original innovation. Its portfolio of 65 companies spans oncology, inflammation/metabolism, gene therapy, AI-enabled healthcare, AI photonic computing, and adjacent deep-tech sectors including new materials and intelligent manufacturing.

The firm operates through 8 equity investment funds with assets under management exceeding 3 billion RMB. Its core product is capital allocation combined with hands-on post-investment support, sourced via a senior team whose backgrounds span pharmaceutical R&D (e.g., Managing Partner Chen Renhai's prior role at Shanghai Target Drug and Debug Pharmaceutical Group), clinical medicine, and prior VC partnerships at Nanjing Kaiyuan and Suzhou Kaifeng Zhengde. Distribution is direct: capital is deployed into portfolio companies across angel, pre-A, A, and A+ rounds, with co-investment partnerships including OrbiMed, Sequoia China, Hankang Capital, Bayer, and Aditum Bio.

The revenue model is standard for an Asian growth-stage VC: recurring management fees on multi-vintage fund AUM, supplemented by carried interest realized from portfolio company exits. Notable realized exits include Leads Biolabs (09887.HK, July 2025, where Ennovation was the 2015 angel and largest external institutional shareholder), TransThera Sciences (02617.HK, June 2025), and LIGHTELLIGENCE (01879.HK, April 2026, world's first AI photonic computing stock). The firm has no disclosed parent company, operates two offices (Shanghai HQ and Nanjing regional), and currently lists 8 named team members.

Name

Ennovation Ventures

Legal name

南京恩然瑞光投资管理中心（有限合伙）

Website

https://ennovationvc.com

Company type

Private

Founded year

2015

Operating status

Operating

Short description

Ennovation Ventures is a China-based venture capital firm founded in 2015 that invests across the global biopharmaceutical and healthcare industry chain, managing 8 funds with over 3 billion RMB AUM and a 65-company portfolio spanning oncology, biopharma, and AI-enabled healthcare.

Ownership category

akta.pro rank

Product category

Venture Capital / Private Equity (Biomedical and Healthcare)

NAICS

All Other Financial Investment Activities (52399), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Venture capital
• Biomedical investing
• Healthcare private equity
• Biopharmaceutical funding
• Equity investment funds

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Fund Management: Manages 8 equity investment funds with over 3 billion RMB in assets under management. Generates revenue through management fees and carried interest from portfolio company exits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Ennovation Ventures is a venture capital firm that invests equity capital from 8 managed funds (over 3 billion RMB AUM) into early to mid-stage biomedical and healthcare companies globally. The firm acts as investor, partner, and co-founder to 65 portfolio companies spanning biopharmaceuticals, medical devices, AI healthcare, and adjacent sectors such as new materials and intelligent manufacturing.

Product overview

Ennovation Ventures is a venture capital firm established in 2015, specializing in biomedicine and healthcare investments. The firm does not offer traditional product or service offerings in the SaaS/application sense. Rather, it provides equity investment services through eight managed funds with over 3 billion RMB in assets, focusing on revolutionary new technologies and products in the global biomedicine and medical health industry chain. The firm has invested in 65 portfolio companies and serves as an investor, partner, and co-founder to innovative biopharmaceutical and healthcare enterprises.

Differentiator

Problem solved

Functional benefit

Products and services

• Equity Investment Fund Management (8 Funds) Management of 8 equity investment funds totaling over 3 billion RMB in AUM, deploying capital into early to mid-stage biomedical and healthcare companies. Revenue is generated through fund management fees and carried interest from portfolio company exits.
• Direct Equity Investment Services Direct equity investment in portfolio companies across seed, angel, and growth stages, with the firm acting as investor, partner, and co-founder to 65 portfolio companies in biopharmaceuticals, medical devices, AI healthcare, new materials, and intelligent manufacturing.

Quantifiable outcome

• Multiple portfolio companies successfully listed on HKEX (Lightelligence, TransThera, Leads Biolabs)
• +1 more outcomes

Named customers7 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core.

• 中国药科大学附属上海高博肿瘤医院 (Shanghai Gaobo Cancer Hospital)coreStrategic or Co-development Partner · 27 December 2024Strategic cooperation with Immunophage for Phase II clinical trial of IPG7236. Professor Li Jin serves as PI.
• Bayer AGcoreStrategic or Co-development Partner · 15 November 2024Hope Medicine holds global exclusive license from Bayer for HMI-115 monoclonal antibody targeting prolactin receptor.
• Aditum BiocoreStrategic or Co-development Partner · 7 November 2024Aditum Bio and Leads Biolabs established Oblenio Bio for tri-specific T cell engager LBL-051 development. Deal worth up to $614 million including $35M upfront and milestones.

Scale indicators4 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• OrbiMed: Global healthcare-dedicated investment firm investing across venture, growth, and public stages in biopharma, medical devices, and diagnostics. Directly comparable as a healthcare-sector specialist VC; recently co-invested with Ennovation in Proviva Therapeutics' A+ round.
• Qiming Venture Partners: China-based VC firm with a dedicated healthcare/biotech practice alongside technology investments. Directly comparable to Ennovation as a China-rooted investor focused on early-to-mid stage healthcare and life sciences companies, including biopharma and medical devices.
• Vivo Capital: Healthcare-focused investment firm with significant Asia-Pacific operations investing across venture and growth stages in biopharma, medical devices, and healthcare services. Directly comparable as a healthcare-sector specialist with comparable deal size and stage in Asia.
• Ally Bridge Group (汇桥资本): Healthcare-dedicated investment firm focused on cross-border biotech investing with significant China exposure. Directly comparable as a healthcare-specialist investor operating between US and China biotech ecosystems with similar stage focus and exit pathways.
• LAV (礼来亚洲基金 / Lilly Asia Ventures): Asia-focused venture capital firm dedicated to life sciences and healthcare investments, with operations in China. Directly comparable to Ennovation as a sector-specialist healthcare/biotech VC based in Greater China with multiple portfolio IPOs and a similar early-to-growth stage investment strategy.

Broad incumbents

• Hillhouse Capital (高瓴资本): Large China-focused investment manager with a dedicated healthcare/biotech investing practice across venture and growth stages. Broader incumbent with substantially more AUM and global LP base, but overlapping Chinese biotech investment focus and HKEX exit pipeline.
• IDG Capital: One of the earliest and largest China-focused venture firms, with a dedicated healthcare investment team covering biopharma, medical devices, and diagnostics. Broader incumbent comparable to Ennovation on Chinese healthcare/biotech early-stage deal-making and LP relationships.
• CMB International Capital (招银国际): China-based investment platform with healthcare venture investing capabilities. Broader financial services incumbent with comparable Chinese biotech investment focus and access to HKEX exit opportunities through parent bank relationships.
• Sequoia China (红杉中国): Major China-focused venture and growth investor with active healthcare and biotech practice. Broader incumbent investing across multiple verticals, but with documented co-investment overlap with Ennovation (e.g., Proviva Therapeutics A+ round) and similar Chinese biotech IPO pipeline.

Emerging players

• Boehringer Ingelheim Venture Fund / Strategic Healthcare Investors: Strategic and corporate venture investors in the global biotech space that participate in rounds alongside specialist Chinese VCs. Comparable to Ennovation as co-investors in Chinese biotech (e.g., Bayer licensing relationship with portfolio company Hope Medicine indicates strategic capital adjacency).

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments10 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ennovation Ventures